Sign in
Taking people in United StatesPhase 1

Testing OM336 in adults with autoimmune low blood cell counts

Tests OM336 given under the skin in adults with autoimmune blood disorders.

Key facts

Who runs it
Lakefront Biotherapeutics West LLC
Where
Ann Arbor, Duarte, Seattle, and Washington D.C., United StatesSee the 4 sitesAlso in 1 other country, 3 sites
Trial code
Registry title
OM336 in Autoimmune Cytopenias
Status
Recruiting
Phase
Phase 1
People taking part
32 people, planned
Started
1 Aug 2025
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • OM336
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an active autoimmune cytopenia. This is a condition where the immune system lowers blood cell counts, such as warm or cold autoimmune hemolytic anemia or immune thrombocytopenia (ITP).

Age
18 Years to 75 Years
Sex
All
Disease stage
Active disease that came back or did not respond to treatment (relapsed/refractory).
Earlier treatment
At least 1 prior treatment is needed. People who had a BCMA-targeted therapy before cannot join.

Main reasons for not taking part

  • Body weight under 55 kg (121 lb)
  • Previous treatment with a BCMA-targeted therapy
  • Serious infection within 3 months of screening
  • Major surgery or spleen removal (splenectomy) within 3 months of screening, or planned during the study
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Active autoimmune cytopenia
  • Relapsed/refractory after ≥1 prior treatment
  • Body weight ≥ 55 kg
  • Willing to comply with and study requirements and procedures

Who cannot take part

  • Previous treatment with a BCMA-targeted therapy
  • Major surgery or splenectomy within 3 months of screening or planned during the study
  • Clinically significant infection within 3 months of screening
  • Pregnant or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 1 other country, 3 sites

  • University of MichiganAnn Arbor, United StatesContact: Study SponsorTaking people
  • City of HopeDuarte, United StatesContact: Study SponsorTaking people
  • Fred Hutchinson Cancer CenterSeattle, United StatesContact: Study SponsorTaking people
  • MedstarWashington D.C., United StatesContact: Study SponsorTaking people

About the trial

What the trial wants to find out

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

The group in the trial

  • OM336 Dose EscalationTreatment being tested

    Participants will receive OM336 via subcutaneous injection in ascending dose cohorts

    Treatment: OM336

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Plain-language title
Testing OM336 in adults with autoimmune low blood cell countsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07083960, who can take part
Record updated
3 September 2026